Skip to main content
The Contraceptive Pipeline Database
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
Adjudin
Product Overview
Alternative Name:
AF-2364
Development Status:
Active Development
Target:
Male
Mode:
Non-hormonal
Delivery Type:
TBD
Duration Type:
Short-acting
Description:
Adjudin specifically affects germ cell adhesion, most notably elongating and elongated spermatids shown in rats, rabbits and beagle dogs. Thus, adjudin induces premature exfoliation of sperms from the seminiferoous epithelium. This leads to a lack of mature spermatozoa in ejaculate and ultimately infertility. Adjudin, as well as H2-Gamendazole, are derivatives of lonidamine. Since adjudin does not deplete the population of undifferentiated spermatogonia or spermatogonial stem cells, spermatogenesis eventually resumes and fertility rebounds.
Updated date:
August 09, 2016
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide
Potential Multi-Purpose Technology (MPT):
No
Regimen:
Once a week; After 2 doses, effective for transient and reversible infertility
Duration:
Laboratory rats remain infertile after 2 doses for approximately 4 weeks
Partner:
Population Council
Status
Project Phase:
Early Development
Project Stage:
Lead Optimization
Status Details:
Contraceptive efficacy has been proven in vivo in rats, rabbits, and beagle dogs.
Programmatic Considerations
Considerations:
Work is in progress to assess the efficacy and optimal dose(s) of adjudin-inclusion mixture B formulation. Also under assessment is a formulation that requires a multi-drug approach using adjudin with an F5-peptide endogenously produced in the testis in vivo.
Additional Information
Additional Information:
Population Council website
Download Product Report
